Relissa™, Berbevis®, Anthocran® Phytosometm: Indena's Hero...
Pharma Tech Outlook
Home » News

Relissa™, Berbevis®, Anthocran® Phytosometm: Indena's Hero Products @ Supply Side West 2023

Pharma Tech Outlook | Wednesday, October 25, 2023

Milan,– RELISSA™, BERBEVIS® and ANTHOCRAN® PHYTOSOMETM: these are the products Indena will focus on during Supply Side West 2023, sharing with all its stakeholders the latest news on its research on nutraceuticals.

 Indena will welcome its guests on October 25th and 26th at Mandalay Bay, Las Vegas, Nv Expo Hall, Booth 5265.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

“We’re happy to be here once again, taking our recent updates to one of the most important trade shows in the world for the nutraceutical industry and to a strategic market like the USA – says Francesca De Rensis, Marketing Director of Indena S.p.A. -. Our botanical ingredients are meant to help people taking care of their health through prevention, lifestyle and nutrition, and we keep working on research, quality and innovation to provide our clients with excellent supplements. Moreover, we’re proud to share with the Supply Side West 2023 visitors what we continuously do for sustainability, which is for Indena a concrete commitment since years. We are waiting for our stakeholders to continue discussing the most relevant topics in the world of nutraceuticals and the responsible approach to business”.

Relissatm: Keep Calm, Sleep Well And Live Better With The Help Of Indena’s Extract From Melissa Officinalis

Sleep is a critical part of our overall health, and the quality and quantity of our sleep are deeply connected to our mental and emotional well-being. Melissa officinalis is a member of the mint family which has been known for centuries and used for various applications thanks to its calming and “anti-stress” action, promoting sleep and relaxation. Indena’s RELISSATM is a new standardized, botanical ingredient clinically validated as support to emotional and sleep health: a new way to balance mood and manage stress. Based on the formulation of lemon balm extract from Melissa officinalis, it’s standardized in hydroxycinnamic acids (17-23% by HPLC) and analyzed for rosmarinic acid content. RELISSATM is formulated with Indena Phytosome™ technology which optimize its biological performances turning a good ingredient (Melissa officinalis) into a great ingredient. Scientific evidences confirms that RELISSATM gives 24 hours of wellbeing, has good interaction with microbiota, has enhanced effect on physiological GABA pathway, is efficacious for radical scavenging and has high tolerability. A complete presentation of the product will be done at Supply Side West by Serena Tongiani, Chief Product Officer of Indena, on October 25th at 1:30-1:50 pm, Supply Side Stage, Boot 5670.

Berbevis®: The Natural Way To Keep The Metabolism Balanced

Berberine is a quaternary ammonium salt derived from isoquinoline alkaloid and it is supported by solid scientific literature proving its health benefits in multifactorial conditions, including the support in controlling healthy blood levels. The genus Berberis represents the main natural source of berberine and Berberis aristata DC is one of the most important species in the genus Berberis. Working on berberine, Indena developed BERBEVIS®, a new and innovative PhytosomeTM composition which optimizes berberine bioabsorption, This PhytosomeTM composition includes both pea proteins, as a natural vegetable protein carrier, and a powerful, natural antioxidant such as grape seed extract to optimize BERBEVIS® tolerability profile.

Clinical evidences show that BERBEVIS® supplementation is the winning multi-target approach to metabolic health maintenance: it optimizes insulin levels effectively and noticeably modulates the blood sugar profile, optimizing both blood glycaemia and insulin. Moreover, a favorable safety profile was reported, with no major adverse events. All in all, BERBEVIS® is a potent, natural health-food ingredient that might help blood sugar control in a plethora of multifactorial challenges, which represent one of the greatest global health challenges of our time.

Anthocran® Phytosometm: A Natural Ally For Women’s Health

Inflammation of the urinary tract and Candida albicans are widespread problems that mainly affect women. For this reason, the prolonged well-being of the female organism can be helped by natural ingredients. Anthocran® PhytosomeTM is Indena’s cranberry extract, a health food ingredient based on PhytosomeTM formulation proprietary technology. Anthocran® PhytosomeTM boasts a unique phytochemical characterization, which makes it the highest quality cranberry extract on the market. It is standardized in proanthocyanidins and contains the full polyphenol profile of natural cranberry, including flavonols, anthocyanins and phenolic acids. Phytosome™ formulation allows to optimize the bioabsorption of phytonutrients and exploit cranberry health benefits.

Recent studies have been carried out by Indena to verify that the complex mixture of proanthocyanidins (PACs), flavonols and phenolic acids contained in Indena’s cranberry extract seems to support the control of biofilm formation as in the case of Candida albicans. The clinical evidence shows that Indena’s cranberry extract PhytosomeTM is a valid supplement for the support of urinary tract health, with a good tolerability profile.

Phytosometm: Indena’s Delivery System To Enhance The Power Of Phytonutrients

Despite their potential for promising health benefits, botanical and natural compounds often need to unlock their full power and overcome several obstacles which together lead to a low oral bioabsorption. PhytosomeTM – a proprietary Technology Platform developed by Indena – is a multi-talented 100% food grade delivery system that optimizes the performance of phytonutrients in multiple ways, allowing to exploit their power and health benefits. In many years, it has been most reliable and customizable solution in the nutraceutical field.

PhytosomeTM is formulated with natural dietary ingredients already existing in the human body (phospholipids) that act as vectors, dynamically reducing the self-aggregation of natural compounds. The resulting functional dispersion allows natural ingredients to interface efficiently with the gut’s ecosystem in terms of bioabsorption and microbiota interactivity, and to be flexibly formulated in several dosage forms and tailor-made solutions. Phytosome™ optimizes biological and technological performances of natural compounds without relying on pharmacological adjuvants or the structural modification of ingredients, maintaining tolerability and safety over time.

Indena: Production As A Part Of Global Governance Sustainability-Oriented

Sustainability has been an approach to governance for Indena for many years. The company makes a major commitment to protecting nature, a source of inspiration but also of business, in innovating technology to address climate change and in taking care of people as the real source of sustainable success.

There are five main global sustainability challenges that Indena constantly addresses, to guide its vision and plans: climate change, loss of biodiversity, waste, social vulnerability and health.

Indena’s main plant at Settala near Milan, which is run according to sustainability principles, starting from an efficient energy management. As an example, Indena is equipping all its European sites with state-of-the-art photovoltaic panels. The total renewable energy self-production by 2023 will be of 5,013, 000 kwhours per year, equivalent to 2,340 Tons of CO2 saved. In 2023, 67% of the energy used by Indena will be self produced, of which almost 23% from renewable sources, and 5,177 Tons of CO2 will be saved. All of Indena’s European factories are certified according to ISO 14001 Environmental Management System and ISO 45001 Occupational Health and Safety Management System. 

More in News

Pharmacy is entering a transformative phase where technology is redefining its role in healthcare delivery. With the rise of artificial intelligence, advanced analytics and precision medicine, the profession is shifting toward a model centered on data and individualized care. Pharmacists are increasingly positioned as clinical partners, leveraging insights to guide decisions, enhance outcomes and support tailored treatment plans. How are AI and data science transforming healthcare? Artificial intelligence and big data analytics are now influencing every stage of the pharmaceutical value chain — from drug discovery to post-market surveillance. Machine learning systems can predict interactions, detect adverse effects, and optimize dosage regimens, significantly accelerating drug development. Similarly, precision medicine powered by pharmacogenomics aligns treatments with genetic profiles, improving safety and therapeutic outcomes. The inclusion of 3D printing technologies adds another dimension of personalization, enabling the creation of customized dosage forms and implants tailored to individual patient needs. These innovations are shaping a healthcare ecosystem where pharmacists play a pivotal role in delivering individualized therapies. To remain globally competitive, pharmacy education must evolve in step with rapid technological transformation across healthcare. Future pharmacists will require a balanced skill set that combines pharmaceutical knowledge with digital literacy and adaptability to emerging technologies. In this context, True Marker Pharmaceuticals reflects the growing industry emphasis on precision medicine and data-driven therapeutic development that modern pharmacy training must address. Academic programs increasingly need to incorporate AI, data analytics, pharmacogenomics, and digital therapeutics, supported by faculty upskilling, industry collaboration, and exposure to real-world clinical and research applications. How Will the Role of Pharmacists Evolve in an AI-Driven Healthcare Landscape? Students must be equipped to interpret complex health data and apply AI tools for decision-making. Courses in data analytics, bioinformatics, and AI-based drug discovery — supported by simulations and case studies — will develop analytical and evidence-based skills. Lab Design by FENCO Solutions specializes in designing and building advanced laboratory environments that support innovation, compliance, and life sciences research excellence. Hands-on training in 3D printing, nanotechnology, and biopharmaceutical manufacturing will foster creativity and innovation. Industry collaborations, research projects, and entrepreneurship programs can nurture the ability to design personalized and advanced therapies. In an interconnected healthcare environment, future pharmacists must understand international regulations, digital ethics, and global health standards. Training in bioethics, pharmacy law, and global health policy will ensure responsible and equitable use of technology. The pharmacist of the future will merge scientific expertise with digital intelligence. Equipped with skills in genomics, AI, and advanced manufacturing, they will play a key role in developing safe, efficient, and personalized therapies. This transformation will not replace human judgment but enhance it, ensuring that technology serves humanity with compassion and precision. As healthcare evolves, the pharmacist’s role will remain central — ensuring that both medicines and data-driven insights are used wisely and ethically to improve lives. ...Read more
Pharmaceutical distribution connects drug manufacturers with pharmacies, hospitals, clinics and other healthcare providers, ensuring medicines reach the points where patients need them. Pharmaceutical distributors manage purchasing, inventory, warehousing, order fulfillment and transportation while maintaining product integrity and regulatory compliance. Their role extends beyond moving products. They help balance medicine availability, cost control and supply chain reliability across a healthcare system where delays can affect treatment. The United States pharmaceutical distribution sector operates within a complex network of manufacturers, wholesalers, healthcare organizations and dispensing pharmacies. Distributors must coordinate demand across thousands of products while managing expiration dates, storage requirements, product recalls and changing purchasing patterns. Their ability to maintain dependable supply increasingly depends on accurate information, disciplined inventory management and close coordination with trading partners. Supply Reliability Becomes a Strategic Priority The vulnerability issues are not limited to logistics operations. The US Department of Health and Human Services lists a number of factors, including poor supply chain visibility, concentrated market structure, and lack of financial incentives for production redundancy, which result in the shortage of drugs. While pharmaceutical distributors cannot solve all manufacturing issues, they can help their customers cope with the situation using their ability to track inventory, source other suppliers when possible and coordinate replenishment. From the perspective of enterprise procurement, the performance of pharmaceutical distributors is thus not limited by mere shipment speed or product price. Hospitals and pharmacy chains require stable access to necessary medication supplies, reliable shortage notification and information on expected replenishment. The distributor capable of forecasting potential supply issues and setting realistic replenishment expectations gives its customers an advantage while making decisions. Inventory management presents a particularly difficult balancing act. Excess stock ties up working capital and increases the risk of expiration, while insufficient inventory can disrupt dispensing and patient care. Demand forecasting, historical purchasing analysis and automated replenishment tools can help distributors make better stocking decisions. Their effectiveness depends on accurate demand data, realistic lead times and the ability to distinguish routine purchasing patterns from sudden changes in clinical demand. Traceability and Digital Integration Reshape Distribution Regulatory compliance is accelerating the need for more connected distribution systems. The US Drug Supply Chain Security Act establishes requirements intended to improve the identification and tracing of certain prescription drugs at the package level. Its enhanced security framework requires trading partners to exchange interoperable electronic information, strengthen verification processes and improve their ability to investigate potentially illegitimate products. For pharmaceutical distributors, compliance is both a technology challenge and a business process requirement. Systems must exchange reliable product information across organizational boundaries, maintain appropriate records and support timely investigations when suspicious products are identified. Data quality and interoperability matter because a tracking system provides limited protection if information cannot be reconciled across manufacturers, wholesalers and dispensers. Cold-chain distribution introduces additional complexity. Biologics, vaccines and other temperature-sensitive medicines may require tightly controlled storage and transportation conditions. Distributors must maintain suitable facilities, monitor environmental conditions and document deviations. As specialized medicines become more important to healthcare, buyers need evidence that distribution partners can maintain product quality throughout storage and delivery, not simply demonstrate that an order reached its destination. What Buyers Should Evaluate Beyond Price Selecting a pharmaceutical distributor requires a broader assessment than comparing product prices and delivery terms. Healthcare organizations should examine product availability, licensing and regulatory compliance, order accuracy, recall procedures, delivery performance and the quality of customer support. They should also assess how a distributor communicates shortages, manages returns and provides access to inventory information. Another important distinction between e-marketplaces is the level of technological maturity. Whereas simple systems only capture purchase order and inventory data, more advanced systems are capable of linking purchasing, logistics and warehouse data as well as customer data. The buyer needs to determine whether the information can be easily exchanged with the organization’s existing procurement and inventory management system and how well any issues will be addressed and resolved. Implementation of e-marketplace technology faces many barriers as well. Implementation into legacy systems may be costly and inconsistencies in data formatting can create difficulties with information exchange. Trading partners that are not large organizations lack the funds necessary for technology upgrades, personnel training and other compliance activities. Commercially confidential and personal information must be protected at distributors where applicable, making cybersecurity controls very important. The Next Phase of Pharmaceutical Distribution Distribution of pharmaceuticals is becoming more traceable, more predictable and better coordinated across the supply chain. Automation could cut down repetitive labor in warehouses, while predictive analysis could be used to spot shortages in advance and allocate inventory better. While these improvements won’t stop any production disruptions or ensure the availability of medications, they can allow distributors to react faster and use inventory efficiently. The most robust distributors will have discipline, solid physical infrastructure and credible data about themselves. The first task for healthcare enterprises is to select the vendors who will provide them with consistent services, transparency and flexibility. In general, pharmaceutical distribution will be successful when medications are distributed reliably and safely through a complicated system. ...Read more
Navigating a complex and highly regulated environment, the pharmaceutical industry must keep pace with evolving regulatory trends to maintain compliance and competitiveness. Technological advancements, changing public health priorities, and global challenges are reshaping the sector, giving rise to key regulatory developments that will define its future. For companies implementing AI, it is essential to align with these standards while ensuring their AI systems are reliable, transparent, and accountable. Regulators are encouraging the use of data from electronic health records, wearable devices, and patient-reported outcomes to supplement traditional clinical trials. Real-world data (RWD) can provide insights into how therapies perform in broader, more diverse populations. Pharmaceutical companies must adapt by investing in data analytics capabilities and partnerships with technology providers. Another critical trend is the growing focus on personalized medicine and advanced therapies. Regulatory agencies are refining pathways to accommodate cell and gene therapies, biologics, and other cutting-edge treatments tailored to individual patients. The programs have stringent requirements for post-approval commitments and long-term safety monitoring. Adopting artificial intelligence (AI) and machine learning (ML) in drug development and regulatory processes is also gaining traction. AI can enhance drug discovery, optimize clinical trial designs, and predict adverse events. Regulatory bodies are beginning to issue guidelines to ensure AI's ethical and transparent use in the pharmaceutical sector. It has outlined its expectations for AI-based medical devices and algorithms, focusing on bias, explainability, and real-world validation. Global harmonization of regulatory standards is another key trend. The COVID-19 pandemic underscored the importance of international collaboration in accelerating vaccine development and approval processes. While this trend simplifies compliance for global pharmaceutical companies, it requires them to stay updated on evolving guidelines and participate in collaborative efforts to ensure consistent implementation. Regulatory scrutiny on environmental sustainability is increasing as well. There is a stronger push for patient-centric approaches in drug development. Incorporating patient-reported outcomes and involving patient advocacy groups can enhance the relevance and acceptance of new therapies, ultimately benefiting patients and manufacturers. The regulatory landscape is evolving to address supply chain resilience and transparency. The COVID-19 pandemic exposed vulnerabilities in global pharmaceutical supply chains, prompting regulators to prioritize measures that ensure uninterrupted access to essential medicines. Enhanced tracking systems, diversification of suppliers, and stricter quality controls are becoming regulatory imperatives. ...Read more
The pharmaceutical industry operates in a highly regulated, complex environment, particularly regarding controlled substance supply chains. Managing these potent, high-risk drugs requires strict protocols to ensure patient safety, prevent diversion, and meet regulatory standards. Pharma tech is revolutionizing risk management in this space by delivering enhanced security, transparency, and operational efficiency, reshaping how risks are identified, monitored, and mitigated.   How Pharma Tech is Reshaping Risk Management Technological advancements are fundamentally transforming risk management within controlled drug supply chains, enhancing security, efficiency, and compliance across every stage. Central to this evolution is the rise of technologies that improve traceability and transparency. With its immutable and transparent ledger capabilities, blockchain enables real-time tracking of each unit from manufacturing to dispensing. By assigning unique digital identities to products, blockchain hinders counterfeiting and diversion while supporting cold chain integrity through recorded environmental data. Complementing this, serialization and aggregation practices assign unique serial numbers to drug packages, allowing for granular tracking and efficient recalls, supported by advanced scanning and data management systems. Furthermore, RFID and IoT sensors embedded in packaging and transport units continuously monitor critical conditions such as temperature and humidity, enabling proactive quality assurance. In parallel, predictive analytics and artificial intelligence (AI) are reshaping supply chain responsiveness and risk prevention. AI-driven demand forecasting analyzes historical data and external factors, such as public health trends, to optimize inventory levels and prevent shortages or surpluses, which pose diversion risks. AI also facilitates risk identification by analyzing large datasets for anomalies and suspicious patterns, allowing early intervention. Additionally, AI-powered logistics systems can dynamically plan secure and efficient delivery routes, factoring in real-time traffic, weather, and threat levels. Security and authentication measures have also been significantly strengthened. Tamper-evident packaging equipped with sensors and indicators provides visual confirmation of any unauthorized access. Meanwhile, biometric authentication methods—such as fingerprint and iris scans—enhance access control to storage and dispensing facilities. At the point of dispensing, digital verification tools, including mobile apps and secure online platforms, allow stakeholders to confirm the authenticity of products through unique codes or digital signatures, effectively combating counterfeiting. Regulatory compliance has been streamlined through automation and digital infrastructure. Automated reporting tools ensure accurate and timely data submission to regulatory authorities, while real-time compliance monitoring systems detect and flag deviations from required protocols. Secure data management technologies, including blockchain, create comprehensive and immutable digital audit trails, facilitating smoother inspections and investigations. Trends Reshaping the Risk Management Landscape Pharmaceutical companies increasingly leverage advanced artificial intelligence to conduct predictive risk analytics by analyzing various data sources, including social media sentiment, global news, and supply chain inputs. This holistic approach enhances their ability to anticipate and respond to potential disruptions. Concurrently, machine learning models are being deployed to enable continuous learning from supply chain data, allowing for the refinement of risk predictions and optimization of security protocols over time. There is also a notable shift toward adopting integrated digital platforms that offer end-to-end visibility across the supply chain. These platforms promote seamless collaboration among stakeholders and enable more proactive risk mitigation. Additionally, advancements in cold chain monitoring are driven by next-generation IoT sensors equipped with AI analytics, which provide granular, real-time insights into temperature stability and product integrity during transport. Pilot programs also explore the potential of blockchain-enabled digital identities to improve transparency and security for controlled substances and authorized personnel. Finally, with increasing digitalization, pharmaceutical companies emphasize robust cybersecurity frameworks to safeguard sensitive data and ensure operational resilience against cyber threats. Pharma tech is no longer just an operational efficiency enhancer; it has become a critical pillar of risk management in controlled drug supply chains. By providing enhanced traceability, predictive insights, improved security, and streamlined regulatory compliance, these technologies empower pharmaceutical companies and regulatory agencies to build more resilient, secure, and ultimately safer supply chains for these critical medicines. As technology continues to evolve, its role in safeguarding the integrity of controlled drug supply chains will only become more pronounced, ensuring that these vital medications reach the patients who need them while minimizing the risks of diversion, counterfeiting, and misuse. ...Read more

Weekly Brief